Home >> Top News >> Quest launches Zika antibody test service

Quest launches Zika antibody test service

Print Friendly, PDF & Email

Oct. 3, 2016Quest Diagnostics has made available an antibody test service that aids the diagnosis of infection with the Zika virus. The service is based on the Zika Immunoglobulin M Antibody Capture Enzyme-Linked Immunosorbent Assay, developed by the Centers for Disease Control and Prevention and authorized for emergency use by the Food and Drug Administration. The CDC has licensed the test to Quest and other national reference laboratories to aid the response to the Zika emergency in the United States.

With the service, Quest Diagnostics provides access to Zika virus antibody and molecular laboratory test services for people in the United States as well as Puerto Rico and other U.S. territories. Health professionals in other countries may also refer specimens for Zika testing to Quest. Testing for Quest’s proprietary Zika RT-PCR test as well as the CDC-based Zika MAC-ELISA is performed at Quest’s Focus Diagnostics, a reference laboratory in San Juan Capistrano, Calif.

More top news


Check Also

Veracyte, Quest agreement, 5/17

May 2017—Veracyte will extend access to its Afirma Gene Expression Classifier through an agreement with Quest Diagnostics. The agreement is intended to meet growing physician demand for innovative genomic testing services to improve thyroid cancer diagnosis.